Richard Mills, MD
Urology · Saginaw, MINPI 1790713949
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,628 of the $4,973 with a category attached, or 72.9%. It is spread thinly across 31 manufacturers, the largest accounting for just 16.7%. Reporting peaked in 2019 at $1,948 and has fallen 86.5% since, to $264 in 2025.
Across 194 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$830
- AbbVie$596
- Astellas Pharma US Inc$586
- Coloplast$564
- Johnson & Johnson$296
- Pfizer$235
- plus $2K from 25 others
Across 35 payments — averaging $6044.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$179K
- Ferring Pharmaceuticals AS$29K
- Ferring International Pharmascience Center US$3K
- Sanofi US Services Inc.$525
What the payments were for
- Travel & lodging$1,00020%
- Food & beverage$3,62873%
- Education$3467%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $830 |
| AbbVie(2 entities) | 36 | $596 |
| Astellas Pharma US Inc | 39 | $586 |
| Coloplast | 8 | $564 |
| Johnson & Johnson(2 entities) | 10 | $296 |
| Pfizer | 11 | $235 |
| Caldera Medical, Inc | 2 | $214 |
| Bayer | 10 | $205 |
| Procept Biorobotics Corporation | 4 | $168 |
| Urovant Sciences Inc | 10 | $156 |
| Teleflex LLC | 3 | $139 |
| Dendreon Pharmaceuticals LLC | 6 | $135 |
| Merck | 1 | $96 |
| Sumitomo Pharma America, Inc. | 5 | $91 |
| Blue Earth Diagnostics | 4 | $83 |
| Myriad Genetic Laboratories, Inc. | 3 | $82 |
| AstraZeneca | 5 | $72 |
| Janssen Scientific Affairs, LLC | 2 | $53 |
| Endo Pharmaceuticals Inc. | 3 | $48 |
| Tolmar Pharmaceuticals, Inc. | 3 | $48 |
| Cook Medical LLC | 2 | $39 |
| Dentsply IH Inc. | 3 | $39 |
| Olympus America Inc. | 2 | $36 |
| KARL Storz Endoscopy-america | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Endo USA, Inc. | 1 | $23 |
| Smith+Nephew | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Dentsply IH AB | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $15 |
| Vertex | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$463
- AMS$356
- Desara$199
- AQUABEAM SYSTEM$119
- SPACEOAR VUE$109
How this compares
$4,973 in reported general payments places this provider in the 65th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 75 | $1,021,590 |
| MyrbetriqMirabegron | 161 | $136,901 |
| GemtesaVibegron | 166 | $136,132 |
| Mirabegron ErMirabegron | 46 | $33,821 |
| Tamsulosin Hcl | 883 | $17,382 |
| ElmironPentosan Polysulfate Sodium | 11 | $13,418 |
| Bicalutamide | 98 | $12,061 |
| Finasteride | 421 | $6,747 |
| Solifenacin Succinate | 86 | $6,282 |
| Tolterodine Tartrate ErTolterodine Tartrate | 37 | $4,286 |
| Potassium Citrate ErPotassium Citrate | 29 | $3,009 |
| Bethanechol Chloride | 35 | $2,635 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 66 | $2,448 |
| Oxybutynin Chloride ErOxybutynin Chloride | 96 | $2,274 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 47 | $1,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $586 | $1,158,491236 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $91 | $136,132166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 400 urology providers in Michigan.
Other urology in Saginaw
- Sanjeev KaulSaginaw$20K
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.